..

Role/Risks of Proton Pump Inhibitors and Infliximab in IBD Patients

Abstract

Lim Vuanghao

Proton Pump Inhibitors (PPIs) are the most generally endorsed class of medicine for the treatment of indigestion and corrosive related issues. They work by obstructing the site of corrosive creation in the parietal cell of the stomach. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases mainly Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab targets TNF, thought to be more related to Th1 cytokines.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证

分享此文章

索引于

相关链接

arrow_upward arrow_upward